DiscoverKorean Startup News[K-Startup Interview] SimfliBIO Challenges NGS with Advanced Liquid Biopsy for Global Cancer Diagnostics Market
[K-Startup Interview] SimfliBIO Challenges NGS with Advanced Liquid Biopsy for Global Cancer Diagnostics Market

[K-Startup Interview] SimfliBIO Challenges NGS with Advanced Liquid Biopsy for Global Cancer Diagnostics Market

Update: 2025-06-14
Share

Description

This episode from WOWTALE presents an interview with SimfliBIO, a Korean startup specializing in liquid biopsy for cancer diagnostics. The article highlights SimfliBIO's novel technology, which boasts significantly higher sensitivity in detecting circulating tumor DNA (ctDNA) compared to existing methods like Next Generation Sequencing (NGS) and PCR. This advanced approach allows for earlier and more precise cancer diagnosiscompanion diagnostics (guiding targeted therapies), and minimal residual disease (MRD) detection. The company aims to challenge global market leaders through clinical trials and eventually expand into various cancer screening and diagnostic applications.

Comments 
loading
In Channel
loading
00:00
00:00
1.0x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

[K-Startup Interview] SimfliBIO Challenges NGS with Advanced Liquid Biopsy for Global Cancer Diagnostics Market

[K-Startup Interview] SimfliBIO Challenges NGS with Advanced Liquid Biopsy for Global Cancer Diagnostics Market

WOWTALE